 |
 |
 |
 |
 |
 |
News from SGC
Posted on Friday 3rd of April 2015
The question of how nerves sense touch, pressure and pain has been a long standing question in physiology. Also the question of how drugs can affect the nerve’s ability to feel pain is critical for design of drugs that will influence our perception of pain. In order to understand how we sense pressure and pain, Assoc. Prof. Liz Carpenter’s group at the SGC, in collaboration with Assoc. Prof. Stephen Tucker in Physics and Prof. Mark Sansom in Biochemistry have looked at a family of human ion channels. These are proteins in nerve membranes that are sensitive to stimuli such as the stretching of a membrane, thus allowing nerves to detect stretch.
Posted on Thursday 2nd of April 2015
SGC scientists come from countries all over the world to do drug discovery research at our laboratories in Canada, UK and Brazil.
Watch videos of SGC members talking about SGC science and open access in 27 different languages like Arabic, Mandarin, Portuguese and Russian, to name a few: http://www.thesgc.org/sgclanguages
SGC’s open access policy of sharing knowledge and research results without restrictions has helped accelerate the discovery of new medicines for many debilitating diseases such as cancer.
Posted on Tuesday 10th of March 2015
Posted on Tuesday 10th of March 2015
Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world.
A $4.3-million (USD) grant from the São Paulo Research Foundation (FAPESP) plus an in-kind contribution of US$ 1.9 million by The University of Campinas (UNICAMP), totalling US$ 6,2 million, will establish Brazil’s first open-access research facility, the Protein Kinase Chemical Biology Centre at the UNICAMP in Brazil.
Posted on Friday 27th of February 2015
Fibrodysplasia ossificans progressiva (FOP) is one of the rarest and most disabling genetic conditions known. The University of Oxford is one of the few places in the world where this disease is being researched, with support from donations.
Posted on Thursday 26th of February 2015
GMEC is pleased to announce the signing of the first collaborative research projects to be launched under theGMEC/Pfizer Rare Diseases agreement which was announced in 2014.
The University of Oxford and Pfizer have agreed three funded research projects in the fields of haematology and neuromuscular disorders. For additional information click here to see the announcement by University of Oxford.
Posted on Wednesday 25th of February 2015
A new Drug Discovery Institute in Oxford focusing on finding new medicines for Azheimer’s is being funded by Alzheimer’s Research UK. The SGC will play a major role in this Institute, providing our expertise in protein production, protein crystallography and medicinal chemistry.
Read more:
Posted on Wednesday 4th of February 2015
This morning at MaRS Discovery District, Merck confirmed its commitment to research and innovation with a $7.5 million contribution to the Structural Genomics Consortium Toronto. (From left to right) Dr. Ronan O'Hagan, Dr. Aled Edwards, The Honourable Reza Moridi, Mr. Chirfi Guindo and Ms. Jennifer Chan. (CNW Group/Merck)
Posted on Monday 15th of December 2014
TORONTO, ON (December 9, 2014) — Dr. Aled Edwards, co-founder and CEO of Structural Genomics Consortium (SGC), has been elected a Senior Ashoka Fellow.
Posted on Monday 24th of November 2014
$2 million grant from the Bill & Melinda Gates Foundation furthers existing research on malaria and TB
Toronto, ON --Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.
Pages
